dc.contributor.author |
Dickgreber, N |
en |
dc.contributor.author |
Stoitzner, P |
en |
dc.contributor.author |
Bai, Y |
en |
dc.contributor.author |
Price, KM |
en |
dc.contributor.author |
Farrand, KJ |
en |
dc.contributor.author |
Manning, KD |
en |
dc.contributor.author |
Angel, Catherine |
en |
dc.contributor.author |
Dunbar, Peter |
en |
dc.contributor.author |
Ronchese, F |
en |
dc.contributor.author |
Fraser, John |
en |
dc.contributor.author |
Backstrom, BT |
en |
dc.contributor.author |
Hermans, Ian |
en |
dc.date.accessioned |
2016-08-17T00:02:50Z |
en |
dc.date.issued |
2009-02-01 |
en |
dc.identifier.citation |
Journal of Immunology, 2009, 182 (3), pp. 1260 - 1269 |
en |
dc.identifier.issn |
0022-1767 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/30021 |
en |
dc.description.abstract |
An efficient pathway of cross-presentation common to a range of dendritic cell (DC) populations was identified by targeting Ag to MHC class II molecules. This finding was achieved by conjugating Ag to M1, which is a modified version of the superantigen streptococcal mitogenic exotoxin Z-2 that binds to MHC class II molecules but cannot directly stimulate T cells. M1 conjugates were efficiently presented to CD4(+) and CD8(+) T cells by bone marrow-derived DC and Langerhans cells in vitro. Whereas nonconjugated Ag was preferentially cross-presented by splenic CD8alpha(+) DC in vivo, M1-conjugated Ag was cross-presented by all dendritic subtypes assessed. Potent effector T cell responses with antitumor activity were elicited when M1 conjugates were injected together with an adjuvant. This method of Ag delivery has significant potential in therapeutic applications |
en |
dc.description.uri |
http://www.jimmunol.org/ |
en |
dc.publisher |
American Association of Immunologists |
en |
dc.relation.ispartofseries |
Journal of Immunology |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/0022-1767/ |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.title |
Targeting Antigen to MHC Class II Molecules Promotes Efficient Cross-Presentation and Enhances Immunotherapy |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.4049/jimmunol.182.3.1260 |
en |
pubs.issue |
3 |
en |
pubs.begin-page |
1260 |
en |
pubs.volume |
182 |
en |
dc.identifier.pmid |
19155471 |
en |
pubs.author-url |
http://www.jimmunol.org/content/182/3/1260.full |
en |
pubs.end-page |
1269 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
81022 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Science |
en |
pubs.org-id |
Biological Sciences |
en |
pubs.org-id |
Science Research |
en |
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
en |
dc.identifier.eissn |
1550-6606 |
en |
pubs.record-created-at-source-date |
2010-09-01 |
en |
pubs.dimensions-id |
19155471 |
en |